HC Wainwright Issues Positive Forecast for Prothena Earnings

Prothena Corporation plc (NASDAQ:PRTA) – HC Wainwright boosted their FY2026 earnings per share estimates for Prothena in a research report issued on Friday, February 20th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings per share of $1.81 for the year, up from their prior estimate of $1.80. HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share. HC Wainwright also issued estimates for Prothena’s Q4 2026 earnings at $1.14 EPS.

Prothena (NASDAQ:PRTA) last issued its earnings results on Thursday, February 19th. The biotechnology company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.01. Prothena had a negative return on equity of 62.53% and a negative net margin of 2,520.57%.The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.67 million.

Other research analysts have also recently issued reports about the stock. UBS Group set a $36.00 price objective on shares of Prothena in a report on Tuesday, October 28th. Citizens Jmp set a $19.00 price target on Prothena in a research note on Monday, December 1st. Piper Sandler increased their price objective on Prothena from $15.00 to $36.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 28th. Weiss Ratings restated a “sell (e+)” rating on shares of Prothena in a report on Monday, December 29th. Finally, Wall Street Zen upgraded Prothena from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Prothena has a consensus rating of “Hold” and a consensus target price of $22.00.

Prothena Trading Up 0.6%

Shares of PRTA stock opened at $9.07 on Monday. The firm has a market capitalization of $488.24 million, a PE ratio of -2.00, a price-to-earnings-growth ratio of 1.89 and a beta of -0.11. The firm has a fifty day simple moving average of $9.24 and a two-hundred day simple moving average of $9.43. Prothena has a 12 month low of $4.32 and a 12 month high of $16.16.

Institutional Trading of Prothena

A number of hedge funds have recently bought and sold shares of the business. Prospera Financial Services Inc bought a new position in Prothena in the 2nd quarter valued at $61,000. Tower Research Capital LLC TRC boosted its holdings in shares of Prothena by 571.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 12,709 shares of the biotechnology company’s stock worth $77,000 after buying an additional 10,815 shares during the last quarter. Corton Capital Inc. bought a new position in Prothena during the second quarter valued at about $85,000. CWM LLC increased its holdings in Prothena by 650.1% during the third quarter. CWM LLC now owns 10,246 shares of the biotechnology company’s stock worth $100,000 after buying an additional 8,880 shares during the last quarter. Finally, ProShare Advisors LLC purchased a new stake in Prothena during the fourth quarter worth about $100,000. 97.08% of the stock is currently owned by institutional investors.

Prothena Company Profile

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.